Top > Search of International Patents > MATURE OVUM MARKER FOR USE IN IN VITRO FERTILIZATION, AND USE THEREOF

MATURE OVUM MARKER FOR USE IN IN VITRO FERTILIZATION, AND USE THEREOF meetings

Foreign code F130007716
Posted date Nov 28, 2013
Country WIPO
International application number 2012JP074486
International publication number WO 2013099376
Date of international filing Sep 25, 2012
Date of international publication Jul 4, 2013
Priority data
  • P2011-284430 (Dec 26, 2011) JP
Title MATURE OVUM MARKER FOR USE IN IN VITRO FERTILIZATION, AND USE THEREOF meetings
Abstract A test method for predicting whether or not pregnancy can be established when an ovum collected from a subject is used in in vitro fertilization, characterized in that the concentration of CNP in a follicular fluid collected together with the ovum upon the collection of the ovum is measured; and an ovum test kit suitable for in vitro fertilization, involving an anti-CNP antibody.
Outline of related art and contending technology BACKGROUND ART
The in-vitro fertilization, has a problem in the fallopian tubes as a treatment for infertility at the beginning of the target person, then it has been widely applied. At present, in Japan is 21 million people in the in-vitro fertilization exceeds a birth, 2008 years of birth of a person by person 50 1 children born in vitro fertilization have been reported by the Society. Women with an increase in late marriage, in the future considered to further increase the ratio. Is performed in the present method, after fertilization, cell division and progresses to a certain culture (8 - cell stage by the time a), for making back to the uterus fertilized eggs. Can be collected at the time of approximately about this may be a large number of ova, edited by Japan Society in the registration of the obstetrics gynecology, back to the uterus in view of preventing the younger the number of fertilized eggs 1 are restricted in principle.
In-vitro fertilization success of one of the keys 1, a good quality of how much the obtained either from the fact that the mature egg. A good quality of the mature ovum in advance is determined and then returned to the uterus fertilized if, in-vitro fertilization success rate is increased, the burden on the patient can be reduced. However at present, the embryos were transplanted into the uterus, from the appearance of the geometry and the like based on the experience of the surgeons has been selected, which could lead to the satisfaction of the pregnancy advance to high embryo there was no clearly distinguished.
The natriuretic peptides, having the step-down the diuretic effect discovered as a natural bioactive peptide in a family of peptide hormones. Up to now, ANP, BNP and CNP are referred to as type 3 in the presence of homology to known. ANP and BNP are already, acute heart failure and heart failure are widely used for diagnostic and clinical applications.
With respect to the CNP, human, pig, expressed in the brain in a rat has been reported, mainly in the central nervous system has been thought to function (non-patent documents 1 and 2). Recently, CNP is within the central nervous system, reproductive organs, and vascular endothelial in the bone is expressed in currently known (Non-Patent Document 3). However, many physiological function that is unknown, the medical applications is not in progress.
Recently, in the follicles of the mouse, the granulosa cell CNP gene, its receptor gene expression and cumulus cells respectively, in a concentration-dependent manner in vitro CNP is surrounded by the cumulus cells inhibit the maturation of oocytes, on the other hand, of the receptor or graf CNP in the follicle of the mutant mice, early reports to resume meiosis, CNP has been produced by granulosa cells is implicated in the regulation of ovum maturation has been suggested (non-patent document 4). However, in the follicular fluid levels detectable CNP peptide reports of whether or not there is, in the follicular fluid is established even in the CNP concentration and the possibility of pregnancy in terms of the relationship is not known at all.
Scope of claims (In Japanese)請求の範囲 [請求項1]
 被験者から採取した卵子が、体外受精において当該卵子を使用した場合に妊娠成立に至るか否かを予測するための検査方法であって、採卵時に卵子と共に採取された卵胞液中のCNP濃度を測定することを特徴とする方法。

[請求項2]
 CNP濃度が免疫学的アッセイによって測定される、請求項1に記載の方法。

[請求項3]
 免疫学的アッセイがRIAである、請求項2に記載の方法。

[請求項4]
 被験者がヒトである、請求項1~3のいずれか1項に記載の方法。

[請求項5]
 抗CNP抗体を含む、体外受精に適した卵子の検査用キット。

[請求項6]
 被験者がヒトである、請求項5に記載のキット。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF FUKUI
  • Inventor
  • MIYAMOTO, Kaoru
  • MIZUTANI, Tetsuya
  • ORISAKA, Makoto
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close